原发肿瘤部位在转移性结直肠癌患者中的相关性:一线临床试验的荟萃分析
该荟萃分析纳入截至2016年10月的一线临床试验,评估原发肿瘤部位在转移性结直肠癌中的意义。结果显示右半结肠癌预后显著差于左半结肠癌(OS的HR 1.56,95%CI 1.43-1.70,P<0.0001)。RAS野生型左半结肠癌患者从标准化疗联合抗EGFR抗体中显著获益,右半结肠癌则化疗联合贝伐珠单抗为治疗选择,但最佳治疗尚未明确。
要点
- 右半结肠癌预后显著差于左半结肠癌,OS的HR为1.56(95%CI 1.43-1.70,P<0.0001)。
- RAS野生型左半结肠癌患者,标准化疗联合抗EGFR抗体较联合抗VEGF治疗显著改善生存(HR 0.71,95%CI 0.58-0.85,P=0.0003)。
- 右半结肠癌患者从标准治疗中获益较差,含贝伐珠单抗方案与更长生存数值上相关(HR 1.3,95%CI 0.97-1.74,P=0.081)。
核心结论
- 该荟萃分析表明原发肿瘤部位在转移性结直肠癌中具有预后意义。
- 研究支持RAS野生型左半结肠癌转移性结直肠癌患者应优先接受抗EGFR抗体治疗。
- 右半结肠癌转移性结直肠癌中,化疗联合贝伐珠单抗是一种治疗选择,但最佳治疗尚未明确。
研究设计与样本
- 对截至2016年10月可获取的一线临床试验进行荟萃分析,评估原发肿瘤部位在转移性结直肠癌患者中的相关性。
- 共纳入13项一线随机对照试验和1项前瞻性药物遗传学研究,区分右半结肠癌和左半结肠癌。
主要发现
- 右半结肠癌与左半结肠癌相比预后显著更差,总生存的HR为1.56(95%CI 1.43-1.70,P<0.0001)。
- 对PRIME和CRYSTAL研究的荟萃分析提示,原发肿瘤部位可预测RAS野生型肿瘤患者从标准化疗联合抗EGFR抗体中的生存获益:左半结肠癌总生存HR 0.69(95%CI 0.58-0.83,P<0.0001),右半结肠癌HR 0.96(95%CI 0.68-1.35,P=0.802)。
- 对FIRE-3/AIO KRK0306、CALGB/SWOG 80405和PEAK研究的荟萃分析表明,RAS野生型左半结肠癌患者从标准化疗联合抗EGFR治疗中获得的生存获益显著大于联合抗VEGF治疗(HR 0.71,95%CI 0.58-0.85,P=0.0003)。
- 在右半结肠癌患者中,标准治疗获益较差,含贝伐珠单抗治疗与更长生存数值上相关(HR 1.3,95%CI 0.97-1.74,P=0.081)。
临床怎么用
- 作者认为,RAS野生型左半结肠癌转移性结直肠癌患者应优先接受抗EGFR抗体治疗。
- 作者指出,右半结肠癌转移性结直肠癌中化疗联合贝伐珠单抗是一种治疗选择,但最佳治疗尚未明确。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Retrospective subgroup analyses suggest that primary tumour location (PTL) has a prognostic importance and relates to response to targeted therapy. METHODS: We conducted a meta-analysis of first-line clinical trials available up to October 2016, which assessed the relevance of PTL in patients with metastatic colorectal cancer (mCRC). Right- and left-sided colorectal cancers were differentiated (RC and LC). RESULTS: In 13 first-line randomised controlled trials and one prospective pharmacogenetic study, RC was associated with a significantly worse prognosis compared with LC (hazard ratio [HR] for overall survival: 1.56; 95% confidence interval [CI]: 1.43-1.70; P < 0.0001). A meta-analysis of PRIME and CRYSTAL study suggests that PTL was predictive of survival benefit from addition of anti-EGFR antibody to standard chemotherapy in patients with RAS wild-type tumour (overall survival, HR for LC: 0.69; 95% CI: 0.58-0.83; P < 0.0001 and HR for RC: 0.96; 95% CI: 0.68-1.35; P = 0.802). A meta-analysis of FIRE-3/AIO KRK0306, CALGB/SWOG 80405 and PEAK study indicates that patients with RAS wild-type LC had a significantly greater survival benefit from anti-EGFR treatment compared with anti-VEGF treatment when added to standard chemotherapy (HR 0.71; 95% CI: 0.58-0.85; P = 0.0003). By contrast, in patients with RC, benefit from standard therapy was poor and bevacizumab-based treatment was numerically associated with longer survival (HR 1.3; 95% CI: 0.97-1.74; P = 0.081). CONCLUSIONS: The present meta-analysis demonstrates that PTL is prognostic in mCRC. Further, it supports the conclusion that patients with left-sided RAS wild-type mCRC should be preferentially treated with an anti-EGFR antibody. In right-sided mCRC, chemotherapy plus bevacizumab is a treatment option, but optimal treatment has yet to be defined.
引用
- Holch JW, Ricard I, Stintzing S, et al. The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. Eur J Cancer. 2016. PMID: 27907852. doi:10.1016/j.ejca.2016.10.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。